[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hand-and-foot-syndrome\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hand-and-foot-syndrome":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":5},"100628133","phase-2-tar-0520-gel-in-hand-and-foot-syndrome-100628133",false,"NCT07457671","TAR-0520 Gel in Hand and Foot Syndrome","A Phase 2a Exploratory Study of TAR-0520 Gel in Prevention of Hand and Foot Syndrome","TARIAN008","Inclusion Criteria:\n\n* Medical diagnosis of breast or colorectal cancer planned to be treated with capecitabine\n* at a dose \\> 1000mg\u002Fm² twice daily every 2 out of 3 weeks as single agent chemotherapy\n* Patients with life expectancy graeter than 12 weeks\n\nExclusion Criteria:\n\n* Patient with medical history of capecitabine treatment\n* patient with pre-existing neuropathy confounding assessement of HFS\n* Patient with Raynaud's syndrome or other vascular peripheral disorders\n* Patient with dermatological lesions on hands or foot","ALL","18 Years",{"count":20,"type":21},25,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","Hand and Foot Syndrome (HFS) is a weii-established and frequent cutaneous adverse event of capecitabine used in the treatment of different cancers.HFS is charectirized by a variety of symptoms ranging from mild discomfort to a painful sensation of palms and sols that could limit functionality and hamper patients on their daily activities.\n\nThe aim of this study is to explore the TAR-0520 gel safety and preventive efficacy of HFS in patients with colorectal and breast cancer patients treated with capecitabine.\n\nIs the product well tolerated locally and systemically ? Is the product reducing frequency and severity of HFS ? Is product improving Quality of Life (QoL) of treated patients ? Each patient will receive the active TAR-0520 gel and they will apply it to both hands,twice daily. Applications will be done 1 hour before each morning and evening capecitabine oral intake.\n\nFeet will be not treated and will serve as controls. In total , this study will follow patients during 4 capecitabine Cycles (each Cycle=21 days) for a total of 12 weeks.\n\nClinical evaluations will take place at Day1 of each Cycle and will be conducted separetaly on hands and feet.",[27],"Hand and Foot Syndrome",[27,29],"Prevention of Hand and Foot Syndrome","NOT_YET_RECRUITING","2026-03-03",{"date":33,"type":34},"2026-03-09","ACTUAL",{"date":36,"type":21},"2026-03",{"date":38,"type":21},"2027-06",{"name":40,"class":41},"Tarian Pharma","INDUSTRY"]